Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia

Soledad E. González, Lorena Regairaz, Martín R. Salazar, Noelia S. Ferrando, Verónica V. González Martínez, Patricia M. Carrera Ramos, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
doi: https://doi.org/10.1101/2021.02.02.21250758
Soledad E. González
1Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorena Regairaz
2Immunology Unit. Children’s Hospital Sor María Ludovica, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martín R. Salazar
3Teaching and Research Service, San Martín Hospital, La Plata, Buenos Aires, Argentina
4Faculty of Medicine, National University of La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrsalazar{at}med.unlp.edu.ar
Noelia S. Ferrando
4Faculty of Medicine, National University of La Plata, Buenos Aires, Argentina
5Hemotherapy Institute of Buenos Aires Province “Dra Nora Etchenique”, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Verónica V. González Martínez
1Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia M. Carrera Ramos
6Pediatric Research Institute “Prof. Fernando E. Vitieri”, Children’s Hospital Sor María Ludovica, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santiago A. Pesci
1Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan M. Vidal
1Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Kreplak
1Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisa Estenssoro
7Intensive Care Unit. San Martín Hospital, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 pneumonia. Early (≤3 days from admission) CPA was associated to decreased mortality in patients in the general ward and in the Intensive Care Unit not requiring mechanical ventilation. This suggests that the favorable effect of CPA might be related both to disease acuity and to the therapeutic window.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

We did not register our study TIMING OF CONVALESCENT PLASMA ADMINISTRATION AND 28-DAY MORTALITY FOR COVID-19 PNEUMONIA since it was an observational study and not an intervention one

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Central Ethics Committee of the Ministry of Health of Buenos Aires Province (Expedient 2020-14965594). The resolution 103/2017 of the Ministry of Health of the Province of Buenos Aires establishes the obligation of registration and accreditation of all the Institutional Ethics Committees at the Central Ethics Committee of the Ministry of Health the Province of Buenos Aires; which is not associated with any institution or organization except the same Ministry, as it is the Ethics Committee of the said body, and evaluates all projects developed by institutions of the Ministry. In the protocol of the present study, the Central Ethics Committee acts as an Institutional Evaluation Committee in use of the powers provided for by Decree 3385/08 as a research project, in which the Ministry of Health of the Province of Buenos Aires acts both as sponsor and center. The Central Committee established that this observational study had an adequate risk- benefit ratio and requested the anonymization of data. The administration of convalescent plasma required signed consent from each patient or legal representative, according to CROCPD-BA regulations (Expedient 2919/2123/2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript is available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 03, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia
Soledad E. González, Lorena Regairaz, Martín R. Salazar, Noelia S. Ferrando, Verónica V. González Martínez, Patricia M. Carrera Ramos, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
medRxiv 2021.02.02.21250758; doi: https://doi.org/10.1101/2021.02.02.21250758
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia
Soledad E. González, Lorena Regairaz, Martín R. Salazar, Noelia S. Ferrando, Verónica V. González Martínez, Patricia M. Carrera Ramos, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
medRxiv 2021.02.02.21250758; doi: https://doi.org/10.1101/2021.02.02.21250758

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)